Ovarian cancer standard of care: are there real alternatives?

Cancer Communications

Giuseppe Tonini¹  Chiara Della Pepa¹  Marilena Di Napoli²  Sabrina Chiara Cecere²  Rosa Tambaro²  Sando Pignata²  Carmela Pisano²  Gaetano Facchini² 

[1] Department of Medical Oncology, Campus Bio-Medico University of Rome, Rome, Italy;Department of Urology and Gynecology, Istituto Nazionale Tumori Fondazione Pascale-Istituto Di Ricovero E Cura A Carattere Scientifico, Naples, Italy

关键词: Ovarian cancer;    maintenance treatment;    antiangiogenic;   

DOI  :  10.5732/cjc.014.10274

学科分类：肿瘤学

来源: Springer

【 摘 要 】

Ovarian cancer remains a major issue for gynecological oncologists, and most patients are diagnosed when the disease is already advanced with a poor chance of survival. Debulking surgery followed by platinum-taxane chemotherapy is the current standard of care, but based on several different strategies currently under evaluation, some encouraging data have been published in the last 4 to 5 years. This review provides a state-of-the-art overview of the available alternatives to conventional treatment and the most promising new combinations. For example, neoadjuvant chemotherapy does not seem to be inferior to primary debulking. Despite its outcome improvements, intraperitoneal chemotherapy struggles for acceptance due to the heavy toxicity. Dose-dense chemotherapy, after showing an impressive efficacy in Asian populations, has not produced equal results in a European cohort, and the results of alternative platinum doublets are not superior to those of carboplatin and paclitaxel. In this setting, adherence to a maintenance therapy after first-line treatment and multiple (primarily antiangiogenic) agents appears to be effective. Although many questions, including the duration of maintenance treatment and the use of bevacizumab beyond progression, remain unanswered, new biologic agents, such as poly(ADP-ribose) polymerase (PARP) inhibitors, nintedanib, and mitogen-activated protein/extracellular signal-regulated kinase (MEK) inhibitors, have emerged as potential therapeutic options in the very near future. Based on the multiplicity of available strategies, the histological and molecular features of the tumor, in addition to patient’s clinical condition and disease state, continue to gain importance in guiding treatment choices.

【 授权许可】

CC BY